{"name":"3D Medicines (Sichuan) Co., Ltd.","slug":"3d-medicines-sichuan-co-ltd","ticker":"","exchange":"","domain":"3dmedicinessichuan.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Gemcitabine & oxaliplatin","genericName":"Gemcitabine & oxaliplatin","slug":"gemcitabine-oxaliplatin","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Envafolimab plus Gemcitabine&Cisplatin","genericName":"Envafolimab plus Gemcitabine&Cisplatin","slug":"envafolimab-plus-gemcitabine-cisplatin","indication":"Advanced solid tumors","status":"phase_2"},{"name":"KN035 plus Gemcitabine & oxaliplatin","genericName":"KN035 plus Gemcitabine & oxaliplatin","slug":"kn035-plus-gemcitabine-oxaliplatin","indication":"Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)","status":"phase_3"}]}],"pipeline":[{"name":"Gemcitabine & oxaliplatin","genericName":"Gemcitabine & oxaliplatin","slug":"gemcitabine-oxaliplatin","phase":"phase_3","mechanism":"Gemcitabine and oxaliplatin are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, with gemcitabine acting as a nucleoside analog and oxaliplatin forming platinum-DNA crosslinks.","indications":["Pancreatic cancer","Biliary tract cancer","Gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Envafolimab plus Gemcitabine&Cisplatin","genericName":"Envafolimab plus Gemcitabine&Cisplatin","slug":"envafolimab-plus-gemcitabine-cisplatin","phase":"phase_2","mechanism":"Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"KN035 plus Gemcitabine & oxaliplatin","genericName":"KN035 plus Gemcitabine & oxaliplatin","slug":"kn035-plus-gemcitabine-oxaliplatin","phase":"phase_3","mechanism":"KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.","indications":["Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)","Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOTkd4M1hlSHFSc3FaTk40MzhjTWZqaS1YZnFxNmRsdHRiVndUM2tVN0w3OGVpZ3daaHBBLV9RMnJGdll5OXBBNXB6WUxHbWp4eTJiUERJTHJhZTlBWUJlUjI4Qk5wTm5mam1uX0JYOUxVX2Q0UU5Jek9vNE9wTDNFcGN6TWRlSkt4d21scUI1RUd2WkNuR3JEUmp5TQ?oc=5","date":"2025-05-20","type":"pipeline","source":"BioWorld News","summary":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody - BioWorld News","headline":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPVFM0ODFnZy14OXMtR1MxTjlaWmhEUXV5c0ZteFdmZVhKR0lrSGtuRlZ6VkVWRUliUnFRRVYxV3VDWEFYdjVvdTIzQ3FkQnBhbEx2NnlTUURxajBDR1JUbm5uYW9wTGZvTnhCRGNwU1A3V0NSa1pjYU03OEd5TlBkMW5NcXRKam52R1pxUjlZVUxTaW9oazMtY1hmVDN6OXpr?oc=5","date":"2023-03-14","type":"pipeline","source":"BioWorld News","summary":"China’s NMPA clears Shengdi’s adebrelimab for extensive SCLC - BioWorld News","headline":"China’s NMPA clears Shengdi’s adebrelimab for extensive SCLC","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}